Shares of BridgeBio Pharma, Inc. (BBIO) rose on Thursday morning after the company reported positive Phase 3 topline results for its oral therapy infigratinib for achondroplasia.
The stock is currently trading at $79.94, up $6.61 or 9.02%, on the Nasdaq. The stock opened at $84.85 after closing Monday at $73.33. The stock has traded between $28.33 and $84.94 in the past 52-week period.
BridgeBio said its phase 3 trial met its primary endpoint, showing statistically significant improvement in annualized height velocity compared to placebo in children with achondroplasia. The therapy also demonstrated the first statistically significant improvement in body proportionality reported in a randomized trial for the condition.
The company plans to meet with regulators to discuss submissions for U.S. and European approval in the second half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.